Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

A first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...

Reports FY24 revenue $36.13M, consensus $37.63M. “We believe that petosemtamab’s receipt of two Breakthrough Therapy designations by the FDA – ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

"Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.